Clinical Research Directory
Browse clinical research sites, groups, and studies.
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
Sponsor: University of Wisconsin, Madison
Summary
The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are: * Is agenT-797 safe to use? * What medical problems do participants have when taking agenT-797? Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.
Official title: UW26004: Phase I Trial of Allogeneic iNKT Cell Therapy (agenT-797) in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation (SCT)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2026-10
Completion Date
2029-10
Last Updated
2026-08-11
Healthy Volunteers
No
Conditions
Interventions
agenT-797
agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Locations (1)
University of Wisconsin - Madison
Madison, Wisconsin, United States